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Raised risks of several cancers have been found in patients with type II diabetes, but there are few data on cancer risk in type I
diabetes. We conducted a cohort study of 28900 UK patients with insulin-treated diabetes followed for 520517 person-years, and
compared their cancer incidence and mortality with national expectations. To analyse by diabetes type, we examined risks separately
in 23834 patients diagnosed with diabetes under the age of 30 years, who will almost all have had type I diabetes, and 5066 patients
diagnosed at ages 30–49 years, who probably mainly had type II. Relative risks of cancer overall were close to unity, but ovarian cancer
risk was highly significantly raised in patients with diabetes diagnosed under age 30 years (standardised incidence ratio (SIR)¼2.14; 95%
confidence interval (CI) 1.22–3.48; standardised mortality ratio (SMR)¼2.90; 95% CI 1.45–5.19), with greatest risks for those with
diabetes diagnosed at ages 10–19 years. Risks of cancer at other major sites were not substantially raised for type I patients. The
excesses of obesity- and alcohol-related cancers in type II diabetes may be due to confounding rather than diabetes per se.
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Diabetes mellitus is the most common metabolic abnormality in
Western populations. It occurs through two different primary
disease processes, type I (insulin-dependent) and type II (non-
insulin dependent), with different patient characteristics. The
metabolic and hormonal antecedents and consequences of
diabetes, and the treatments for it, might affect the risk of cancer.
Most studies of cancer risks in patients with diabetes have related
to type II diabetes. Raised risks have been found, although not
entirely consistently, for endometrial, breast, renal, gallbladder
and liver cancers (Kessler, 1970; Armstrong et al, 1976; Ragozzino
et al, 1982; Green and Jensen, 1985; O’Mara et al, 1985; Adami et al,
1991; La Vecchia et al, 1994; Hjalgrim et al, 1997; Wideroff et al,
1997; Verlato et al, 2003), but interpretation is uncertain because
of potential confounding by obesity and alcohol consumption.
Pancreatic cancer risk has been found raised (Everhart and
Wright, 1995), but there is uncertainty about the direction of
causation, because pancreatic cancer can cause diabetes.
The aetiology of type I diabetes is not related to obesity or
alcohol use, and the diabetes generally occurs well before the ages
at which pancreatic cancer is prevalent. The only studies of cancer
risk in patients with type I diabetes, however, have been relatively
small – cohorts totalling 2400 patients (Hjalgrim et al, 1997) and a
few case–control data (O’Mara et al, 1985) – and hence of limited
power. Analyses of cancer risk by duration since diagnosis of
diabetes could potentially illuminate causality, but cohort analyses
of this factor have only been conducted for 1500 patients (Hjalgrim
et al, 1997). We examined cancer risks in a UK cohort of 28900
patients with insulin-treated diabetes of known date of diagnosis,
most aged under 30 years at diagnosis of diabetes and therefore
probably with type I diabetes.
MATERIALS AND METHODS
The Diabetes UK (formerly British Diabetic Association (BDA))
cohort consists of 28900 UK resident patients with insulin-treated
diabetes who were under age 50 years at diagnosis of this disease.
A total of 12893 were identified in a national register of childhood
cases assembled by the BDA from 1972 to 1986, and the rest were
recorded in population-based geographical registers for various
parts of the UK during 1972–1993, varying in their dates of data
collection and the ages at diagnosis that were included. Details of
the registers can be found in Laing et al (1999).
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component registers were combined, and identification details of
the patients were sent to the National Health Service Central
Registers (NHSCRs) for England & Wales and Scotland, and to the
Central Services Agency (CSA) for Northern Ireland. The files of
the NHSCRs and CSA are virtually complete population registers
for their countries, and enabled the NHSCRs and CSA to provide
us with ‘flagging’ information on all deaths and emigrations in the
cohort up to the present. We coded cause of death using the
revision of the International Classification of Diseases (ICD) in
force at the time of death, and then bridge coded to ICD9 (World
Health Organization, 1977). For each cohort member, we
calculated person-years at risk by 5-year age group, sex, calendar
year and country of residence, starting from the date of
registration in the study or age 1 year, whichever was later, and
ending at 30th June 2003, or the date of death, 85th birthday,
emigration or other loss to follow-up, if earlier. We censored
follow-up at the 85th birthday because cause of death information
is relatively unreliable beyond that age. We omitted person-years
and deaths under the age of 1 year because national mortality rates
by subdivisions of this age group are not available, and neonatal
deaths were not coded by underlying cause in England and Wales
through most of the study period.
Mortality in the cohort was compared with that in the general
population by calculation of standardised mortality rates (SMRs).
These were calculated as the ratio of the observed number of
deaths to the expected number based on application of age-, sex-,
calendar year- and country-specific person-years at risk in the
cohort to the corresponding mortality rates in the general
population of England and Wales (for the English and Welsh
cases) or Scotland (for the Scottish and Northern Irish cases). The
use of Scottish data for both of the latter countries was necessary
because Northern Irish data for the full period were not available
to us in computer-readable form. As the two countries are fairly
similar in mortality and cancer rates and Northern Ireland
represented less than 5% of the subjects in the study, any
consequent error will have been negligible.
Cancer incidence data for 1971 onwards are recorded on the
NHSCRs (but not ‘flagged’ at the CSA), based on cancer
registrations from population-based regional cancer registries.
Cancer incidence data for the study cohort were therefore sent to
us from the NHSCRs for the English, Welsh and Scottish cohort
members. Cancer incidence was analysed similarly to mortality, by
calculation of standardised incidence ratios (SIRs), with exceptions
as follows: follow-up was censored at 31st December 2001 for
England and Wales and 31st December 1998 for Scotland, because
more recent data are not yet complete; Northern Ireland was
omitted because cancer registration data for cohort members there
could not be gained by flagging; and risk of nonmelanoma skin
cancer was not analysed because registration of it is highly
incomplete (Swerdlow et al, 2001).
We did not have individual data on type of diabetes, but in
insulin-treated patients age at diagnosis of diabetes gives a good
proxy (Laakso and Pyo ¨ra ¨la ¨, 1985), and it has been usual to divide
analyses at age 30 years (O’Mara et al, 1985; Moss et al, 1991; Kjaer
et al, 1992; Hjalgrim et al, 1997; Swerdlow et al, 2004) to give a
younger group who are almost all type I, and an older one who are
largely type II. As well as analyses for the cohort overall, therefore,
we also conducted separate analyses for patients aged under 30
years at diagnosis of diabetes, of whom we calculate that at least
94% will have had type I diabetes (Laing et al, 1999), and for those
aged 30–49 years at diagnosis, who will have been mainly type II
(we estimate 64% type II and 36% type I, based on published data
on insulin-dependent diabetes by age (Laakso and Pyo ¨ra ¨la ¨, 1985)).
The 95% confidence intervals (95% CI) and tests for trend were
calculated assuming a Poisson distribution (Breslow and Day,
1987). Whether two SMRs differed was tested by an exact method
(Breslow and Day, 1987). All P-values presented are two-sided.
RESULTS
A total of 29701 patients with insulin-treated diabetes diagnosed
under age 50 years were identified in the component registers of
the study, of whom 27 were excluded because diabetes was
secondary to a congenital disease (largely cystic fibrosis), 35
because of faulty or incomplete data at registration and 334
because it was unknown whether diagnosis was at ages under 30 or
30–49 years. Of the remainder, 405 (1.4%) patients could not be
traced at the NHSCRs and CSA, and the remaining 28900 formed
the study cohort. A total of 23834 of the patients were diagnosed at
ages under 30 years, and 5066 at ages 30–49 years (Table 1); 15085
were diagnosed before 1980, 13715 later and 100 at an unspecified
date; 15688 were male and 13212 female subjects.
During follow-up there were 3861 deaths, 221 losses to follow-up
through emigration or otherwise leaving the National Health
Service, 88 patients whose follow-up was censored when they
reached age 85 years, and 24730 subjects who reached the end of
follow-up alive under age 85 years; 20676 of these latter were still
under age 50 years. Follow-up was for a total of 520517 person-
years, an average of 18.0 years per subject. Of 2301 deaths in men,
228 were from cancer, and of 1560 in women, 150 were from cancer.
In all, 582 cancer registrations other than nonmelanoma skin
cancer were recorded in the cohort, 305 in men and 277 in women.
Table 2 shows cancer mortality in each sex in patients diagnosed
with diabetes under age 30 years and in those diagnosed at 30–49
years. In the former group, there was a significant excess of deaths
from cancer of the ovary (SMR 2.90; 95% CI 1.45–5.19), but not of
any other cancer, including cancer of the pancreas (SMR 0.91; 95%
CI 0.25–2.32). In the patients diagnosed with diabetes at ages 30–
49 years, there was no raised risk of ovarian cancer (P¼0.016
compared with the risk in the younger-onset diabetes patients),
but there was a significant decrease in deaths from cancer of the
nervous system (SMR 0.25; 95% CI 0.03–0.91) and nonsignifi-
cantly raised risks for several tumours previously reported at
raised risk in patients with diabetes – cancers of the corpus uteri,
pancreas, gall bladder and kidney (although not liver cancer).
Subdividing the ovarian cancer risk more finely by age at onset of
Table 1 Cohort by age at diagnosis and year of diagnosis of diabetes,
country of residence, year of entry to cohort and sex
Male Female Total
Age at diagnosis of diabetes (years)
a
0–14 9503 8818 18321
15–29 3184 2229 5413
30–49 2944 2122 5066
Year of diagnosis of diabetes
a
o1960 681 575 1256
1960–1969 1212 1027 2239
1970–1979 6272 5318 11590
1980–1989 6150 5131 11281
X1990 1316 1118 2434
Country of residence
England and Wales 9163 7852 17015
Scotland 6041 4860 10901
Northern Ireland 484 500 984
Year of entry to cohort
1972–1979 4147 3684 7831
1980–1989 7307 6077 13384
1990–1993 4234 3451 7685
Total 15688 13212 28900
aOmitting 100 patients diagnosed under age 30 years, for whom the exact age and
year of diagnosis is not known.
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with diabetes incident under age 10 years, 4.56 (95% CI 1.67–9.92;
P¼0.005) for diabetes at ages 10–19 years and 1.94 (95% CI 0.53–
4.97) for diabetes at ages 20–29 years (not in table).
Incidence of ovarian cancer was also significantly increased in
patients with diabetes of onset under age 30 years (Table 3), but
there were not significantly raised or diminished SIRs for any
other cancer site in this age group. Similarly to the mortality
results, the SIR was greatest for those with diabetes incident at ages
10–19 years (SIR 2.90; 95% CI 1.32–5.50; P¼0.01). The
histological types of the 16 ovarian cancers occurring in this age
group were six cystic, mucinous or serous, two germ cell, two
adenocarcinomas, one granulosa cell, one Brenner cell and four
unspecified cancers. In patients with diabetes incident at ages 30–
49 years, there was significantly reduced incidence of prostate
cancer and of nervous system cancer; all cases of the latter were
gliomas. There was also a borderline significant excess of
endometrial cancer in the same age group, but no raised risk of
ovarian cancer (P¼0.018 compared with the risk in the younger-
onset diabetes patients).
Table 2 Cancer mortality risks by age at onset of diabetes: selected sites
Age at onset of diabetes (years)
o30 30–49
ICD9 code Cancer site No. SMR (95% CI) No. SMR (95% CI)
150 Oesophagus 5 0.97 (0.31–2.26) 15 1.15 (0.64–1.90)
151 Stomach 5 0.94 (0.31–2.20) 9 0.66 (0.30–1.25)
153–154 Colon and rectum 6 0.52 (0.19–1.13) 29 1.01 (0.67–1.44)
155 Liver 1 0.50 (0.01–2.79) 4 1.01 (0.27–2.58)
156 Gall bladder 1 2.43 (0.06–13.52) 2 1.81 (0.22–6.55)
157 Pancreas 4 0.91 (0.25–2.32) 16 1.44 (0.82–2.33)
162 Lung 27 0.96 (0.63–1.39) 67 0.84 (0.65–1.06)
174, 175 Breast 10 0.74 (0.36–1.37) 17 0.86 (0.50–1.38)
179, 182 Corpus uteri 1 1.30 (0.03–7.26) 4 2.13 (0.58–5.45)
183 Ovary 11 2.90 (1.45–5.19)** 6 0.86 (0.32–1.87)
185 Prostate 1 0.30 (0.01–1.67) 9 0.73 (0.33–1.38)
188 Bladder 2 0.80 (0.10–2.90) 3 0.39 (0.08–1.14)
189 Kidney 1 0.34 (0.01–1.89) 8 1.30 (0.56–2.56)
191, 192 Nervous system 7 0.78 (0.31–1.60) 2 0.25 (0.03–0.91)*
196–199 Primary unknown 7 0.82 (0.33–1.69) 23 1.12 (0.71–1.68)
200, 202 Non-Hodgkin’s lymphoma 5 0.89 (0.29–2.08) 10 1.35 (0.65–2.47)
204–208 Leukaemia 7 0.87 (0.35–1.80) 8 1.46 (0.63–2.87)
140–208 All malignancies 123 0.90 (0.75–1.08) 255 0.93 (0.82–1.05)
ICD¼International Classification of Diseases; SMR¼standardised mortality ratio; CI¼confidence interval. *Po0.05. **Po0.01.
Table 3 Cancer incidence risks by age at onset of diabetes: selected sites
Age at onset of diabetes (years)
o30 30–49
ICD9 code Cancer site No. SIR (95% CI) No. SIR (95% CI)
150 Oesophagus 4 1.06 (0.29–2.73) 15 1.49 (0.83–2.46)
151 Stomach 7 1.20 (0.48–2.47) 12 0.77 (0.40–1.35)
153–154 Colon and rectum 14 0.71 (0.39–1.19) 52 1.11 (0.83–1.46)
155 Liver 1 0.70 (0.02–3.92) 7 2.46 (0.99–5.07)
156 Gall bladder 0 — 1 0.57 (0.01–3.19)
157 Pancreas 5 1.36 (0.44–3.18) 12 1.30 (0.67–2.27)
162 Lung 27 1.14 (0.75–1.65) 56 0.81 (0.61–1.05)
172 Melanoma 20 1.21 (0.74–1.86) 9 1.20 (0.55–2.29)
174, 175 Breast 34 0.87 (0.60–1.21) 41 0.87 (0.62–1.17)
179, 182 Corpus uteri 4 1.20 (0.33–3.08) 12 1.84 (0.95–3.22)
180 Cervix 10 0.72 (0.34–1.32) 7 1.48 (0.60–3.06)
183 Ovary 16 2.14 (1.22–3.48)** 6 0.72 (0.26–1.57)
185 Prostate 6 0.84 (0.31–1.82) 15 0.57 (0.32–0.94)*
186 Testis 13 0.93 (0.49–1.59) 1 0.77 (0.02–4.27)
188 Bladder 7 0.91 (0.37–1.88) 20 1.00 (0.61–1.55)
189 Kidney 2 0.43 (0.05–1.54) 10 1.13 (0.54–2.08)
191, 192 Nervous system 14 1.02 (0.56–1.72) 2 0.26 (0.03–0.94)*
196–9 Primary unknown 5 0.65 (0.21–1.51) 15 0.81(0.45–1.34)
200, 202 Non-Hodgkin’s lymphoma 14 1.13 (0.62–1.89) 12 1.00 (0.52–1.74)
204–208 Leukaemia 10 0.90 (0.43–1.65) 5 0.69 (0.22–1.61)
140–172, 174–208 All malignancies except nonmelanoma skin cancer 241 0.95 (0.84–1.08) 341 0.95 (0.85–1.05)
ICD¼International Classification of Diseases; SIR¼standardised incidence ratio; CI¼confidence interval. *Po0.05. **Po0.01.
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any consistent patterns except that the raised pancreatic cancer
risk in patients with diabetes diagnosed at ages 30–49 years was
limited to men (SMR 1.72; 95% CI 0.89–3.01. SIR 1.97; 95% CI
0.98–3.53), and the lung cancer deficit in the same age group was
most pronounced in women (SMR 0.58; 95% CI 0.31–0.99. SIR
0.53; 95% CI 0.28–0.90; P¼0.02). With regard to sites for which
sex differences in cancer relative risk in patients with diabetes have
been reported in the literature, colorectal cancer, for which greater
incidence risk in males has been reported (Will et al, 1998), did not
show consistently greater SIRs or SMRs in males, and renal cancer,
for which greater female SIRs or SMRs have been reported
(Lindblad et al, 1999), did not show greater SIRs or SMRs in female
subjects. Analyses of breast cancer risk separately at attained ages
under 50 years, and 50 years and above, as a proxy for
premenopausal and postmenopausal ages, were hampered by
small numbers, but gave no significant results and no indication of
systematically different risks by menopausal status.
When cancer mortality risks were analysed by time since onset
of diabetes (Table 4), there was no trend for cancers overall. All
ovarian cancer deaths in women with diabetes diagnosed under
age 30 years occurred more than 10 years after diabetes diagnosis,
with the greatest excess beyond 40 years (SMR 6.0; 95% CI 2.4–
12.4; Po0.001). In the patients diagnosed with diabetes at ages 30–
49 years, the modest excess of pancreatic cancer deaths did not
reflect raised risk at any particular point in follow-up. Lung cancer
mortality risks in patients with diabetes diagnosed at ages 30–49
years diminished significantly with longer follow-up, but this was
not apparent, based on smaller numbers, for those with young-
onset diabetes.
Analyses of cancer incidence risks by duration of diabetes were
based on shorter follow-up (see Materials and Methods) and are
therefore not shown. Lung cancer risks in patients diagnosed with
diabetes at ages 30–49 years generally diminished with time, and
all ovarian cancers in patients with diabetes diagnosed under age
30 years occurred more than 10 years after diabetes diagnosis.
DISCUSSION
The most striking, and unexpected, finding of our study was the
highly significant excess of ovarian cancer in women with insulin-
treated diabetes diagnosed at young ages (i.e. those who
presumptively had type I diabetes). There are few previous data
on this risk: a nonsignificant odds ratio of 2.0 based on two cases
(O’Mara et al, 1985) and a relative risk of 0.6 based on one case
(Weiderpass et al, 2002b). As in previous studies (Kessler, 1970;
Ragozzino et al, 1982; O’Mara et al, 1985; Adami et al, 1991; La
Vecchia et al, 1994; Adler et al, 1996; Wideroff et al, 1997;
Weiderpass et al, 2002b), we did not find a raised risk of ovarian
cancer in women with older onset (i.e. largely type II) diabetes.
Ovarian cancer rates might be raised in patients with diabetes via
effects of hyperinsulinaemia on the ovary (Adler et al, 1996), but
such an effect (endogenous or exogenous) could apply to type II as
well as type I diabetes. Raised IGF1 levels have been proposed as a
mechanism (Weiderpass et al, 2002b), but bioavailable IGF1 is
decreased in type I diabetes (Saukkonen et al, 2004). Shared
environmental or genetic aetiological factors for type I diabetes
and ovarian cancer could in principle be an explanation, but we
know of no such factors. Chance is also a possibility.
It is a limitation that we do not have individual data on
menstrual or reproductive factors in our cohort, but menstrual
factors in studies of women with type I diabetes have been in a
direction to give diminished, not raised, risk of ovarian cancer:
episodes of amenorrhoea are more frequent in women with
insulin-dependent diabetes than in women in general (Kjaer et al,
1992); menarche is delayed in women with diabetes incident under
age 10 years (Kjaer et al, 1992); and limited evidence suggests that
menopause is considerably younger in women with childhood
onset type I diabetes (Dorman et al, 2001). Oral contraceptive (OC)
use is protective against ovarian cancer (Weiss et al, 1996), and
there is evidence that OC use is less common in patients with
diabetes (Dorman et al, 2001), because of potential side effects. The
expected effect on ovarian cancer risk would be too small,
however, to explain our findings. It is unclear whether parity
differs between women with type I diabetes and other women
(Dorman et al, 2001), but the differences would need to be very
large to explain our results. We know of no evidence on
oophorectomy prevalence in women with diabetes. If it were
reduced this could in principle raise ovarian cancer rates, but
oophorectomy rates are too low in the UK (Swerdlow et al, 2001)
for this plausibly to explain the study findings.
There is inconclusive evidence that ovarian cancer risk may be
increased by raised androgen levels (Risch, 1998), and serum
androgen levels have been found raised in menstruating women
with type I diabetes (Djursing et al, 1985). Free testosterone levels,
however, are raised in women with type II diabetes (Andersson
Table 4 Cancer mortality risks by duration since diagnosis of diabetes: selected cancer sites
Duration (years)
0–9 10–19 20–29 30–39 X40
ICD9 code Cancer site No. SMR No. SMR No. SMR No. SMR No. SMR
Diabetes diagnosed at ages o30
a
162 Lung 0 — 0 — 6 1.31 8 0.90 13 0.97
174, 175 Breast 0 — 3 1.50 3 0.63 3 0.87 1 0.33
183 Ovary 0 — 1 2.16 3 3.12 0 — 7 6.01***
140–208 All malignancies
b 9 0.92 15 0.80 30 1.02 25 0.77 43 0.95
Diabetes diagnosed at ages 30–49
c
157 Pancreas 2 3.14 3 0.99 7 1.61 2 0.77 2 3.75
162 Lung 6 1.53 21 1.00 29 0.89 11 0.58 0 —
d
174, 175 Breast 1 0.40 6 0.88 6 0.93 3 0.92 1 1.53
183 Ovary 1 1.56 3 1.30 1 0.40 1 0.78 0 —
140–208 All malignancies 18 1.02 72 0.97 109 1.04 45 0.71 11 0.84
ICD¼International Classification of Diseases; SMR¼standardised mortality ratio. ***Po0.001.
aPerson-years for the duration categories shown are 176795, 174854, 85680,
14650 and 6883, respectively.
bOne death in Table 2 not included here because exact duration since diagnosis is not known.
cPerson-years for the duration categories shown are
15036, 23568, 15218, 5497 and 817, respectively.
dTrend in risk with duration significant, P¼0.01.
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yet al, 1994). Polycystic ovary syndrome (PCO), which includes
raised androgen levels, has been associated with increased risk of
ovarian cancer (Schildkraut et al, 1996) and with type I diabetes
(Escobar-Morreale et al, 2000). An association of PCO also exists,
however, with type II (Rajkhowa et al, 2000).
Type I and type II diabetes differ greatly in mean age at onset, so
the restriction of ovarian cancer risk to type I might be a
consequence of hormonal factors acting specifically at puberty or
reproductive ages. For instance, total and free serum testosterone
levels are raised in late puberty in girls with type I diabetes (Meyer
et al, 2000), but presumably would not be abnormal at puberty in
women with type II diabetes, which is incident much later. We
found greatest ovarian cancer risk for women with diabetes
incident around pubertal ages.
Studies of predominantly type II diabetes patients have generally
shown raised risks of endometrial, renal, gall bladder, liver and
pancreatic cancers, inconsistently raised risks of breast and
colorectal cancers and non-Hodgkin’s lymphoma, and diminished
risk of prostate cancer (Kessler, 1970; Armstrong et al, 1976;
Ragozzino et al, 1982; Green and Jensen, 1985; O’Mara et al, 1985;
Adami et al, 1991, 1996; La Vecchia et al, 1994; Everhart and
Wright, 1995; Zahm et al, 1995; Hjalgrim et al, 1997; Weiderpass
et al, 1997, 2000, 2002a; Wideroff et al, 1997; Will et al, 1998;
Lindblad et al, 1999; Verlato et al, 2003; Coker et al, 2004).
Endometrial, postmenopausal breast, renal and less certainly gall
bladder cancer risks have also been associated with obesity
(International Agency for Research on Cancer, 2002), so the
association of these cancers with type II diabetes might be a
consequence of confounding by obesity. Oestrogen levels affect
endometrial cancer risk (Grady and Ernster, 1996), but data are
inconsistent on whether postmenopausal women with diabetes
have raised oestrogen levels (Nyholm et al, 1989; Andersson et al,
1994). Possible mechanisms suggested for liver cancer in diabetes
have included alcohol consumption and hepatitis (Verlato et al,
2003). The reduced prostate cancer risk might relate to reduced
testosterone levels (Ando ` et al, 1984).
Our data for patients aged 30–49 years, who primarily had type
II diabetes, showed risks raised somewhat for endometrial, liver
and pancreatic cancers, slightly for renal and colorectal cancers
and not raised for gall bladder or breast cancers and NHL, with
reduced risk of prostate cancer. We did not find appreciably raised
risks of these tumours in patients with diabetes incident aged
under 30 years, that is, largely type I. Type I diabetes aetiology,
unlike type II, appears unconnected with obesity or alcohol.
Previous data for type I diabetes have been based on very small
numbers for endometrial, renal, pancreatic, breast and prostate
cancers (O’Mara et al, 1985; Hjalgrim et al, 1997; Weiderpass et al,
2000) and absent for gall bladder and liver cancers. Although with
uncertainty from wide confidence intervals, our data are
compatible with the idea that the raised risk in type II diabetes
for obesity- and alcohol-related tumours may reflect confounding
by obesity and alcohol, rather than aetiology by diabetes per se.
The diminishing risks of lung cancer mortality with longer
follow-up of our older-diagnosed diabetes patients may reflect
selective survival of nonsmokers, given the very high cardiovas-
cular mortality of older patients with diabetes. The few cohort
studies that have published on nervous system cancer in patients
with diabetes did not find decreased risk (O’Mara et al, 1985;
Adami et al, 1991; Wideroff et al, 1997), so the significantly
reduced risk in our patients with older-diagnosed diabetes may
have been a chance finding, especially as there is no obvious
mechanism. Brain tumour prevalence at autopsy has been found
reduced in patients with diabetes, but the deficit was solely for
glioma (Aronson and Aronson, 1965), whereas in our cohort all the
brain tumours were gliomas.
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